U.S. Bank has provided the financing to help develop
apotentially life-saving therapeutic for non-Hodgkin's lymphoma,marking the first
time the New Market Tax Credit (NMTC) program hasbeen used to support a biopharmaceutical
company. As part of afinancing arranged with Accentia Biopharmaceuticals, Inc.,
U.S. Bank purchased $4.6 million of NMTCs as part of aninvestment in a subsidiary
of Biovest International, Inc.